Refametinib — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	0	0	0	5	0	—	—	Feb 5, 2013
Malignant Liver Neoplasm	Phase2	Phase 2	0	0	0	2	0	—	—	Sep 16, 2013

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Curated evidence

Clinical evidence (4)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KRAS Mutation2
Refametinib + Sorafenib

Clinical trials

Trials with this intervention (5)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–5 of 5 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01915589	Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)	completed	Phase 2	16	BayerINDUSTRY	17	Apr 8, 2021	clinicaltrials
NCT01915602	Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)	completed	Phase 2	14	Bayer